Overview

Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Status:
Not yet recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well polarized dendritic cell (aDC1) vaccine, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 vaccine contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body?s natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if aDC1 vaccine, interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

Phase:

Phase 2

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Benzenesulfonamide
Celecoxib
Immune Checkpoint Inhibitors
Interferon alpha-2
Interferon-alpha
Interferons
Poly I-C
poly(I).poly(c12,U)
Vaccines